OROS methylphenidate for the treatment of adults with attention-deficit/ hyperactivity disorder

Expert Review of Neurotherapeutics

Volumn 9, Issue 8, 2009, Pages 1121-1131

  Ramos Quiroga, J Antoni ^a,b   Corominas, Margarida ^a   Castells, Xavier ^a   Bosch, Rosa ^a,b   Casas, Miguel ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

ADHD; Adults; Methylphenidate; OROS

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; DEXMETHYLPHENIDATE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; MODAFINIL; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HEADACHE; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; MORNING DOSAGE; NAUSEA; NERVOUSNESS; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SEDATION; SIDE EFFECT; VITAL SIGN; XEROSTOMIA;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; GUIDELINES AS TOPIC; HUMANS; METHYLPHENIDATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70349334276     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.65     Document Type: Review

References (77)

1. Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J. Atten. Disord. 9(2), 384-391 (2005). Comprehensive study on the prevalence and symptomatology of adults with attention-deficit/hyperactivity disorder (ADHD). (Pubitemid 41608110)
2. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 366(9481), 237-248 (2005).
3. Adler LA, Chua HC. Management of ADHD in adults. J. Clin. Psychiatry 63(Suppl. 12), 29-35 (2002).
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). Text Revision. Washington DA (Eds). The American Psychiatric Association, WA, USA (2000).
5. Kooij JJ, Buitelaar JK, van den Oord EJ, Furer JW, Rijnders CA, Hodiamont PP. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol. Med. 35(6), 817-827 (2005).
6. Kessler RC, Adler L, Barkley R. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am. J. Psychiatry 163(4), 716-723 (2006). (Pubitemid 44464584)
7. Lamberg L. ADHD often undiagnosed in adults: appropriate treatment may benefit work, family, social life. JAMA 290(12), 1565-1567 (2003). Practice references with special interest for clinicians. (Pubitemid 37430375)
8. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr. Psychiatry 37(6), 393-401 (1996). (Pubitemid 26383062)
9. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 63(Suppl. 12), 10-15 (2002).
10. Biederman J, Faraone SV. The effects of attention-deficit/hyperactivity disorder on employment and household income. Med. Gen. Med. 8(3), 12 (2006). (Pubitemid 44144853)
11. Biederman J, Petty CR, Fried R et al. Educational and occupational underattainment in adults with attention-deficit/hyperactivity disorder: a controlled study. J. Clin. Psychiatry 69(8), 1217-1222 (2008).
12. Biederman J. Impact of comorbidity in adults with attention-deficit/ hyperactivity disorder. J. Clin. Psychiatry 65(Suppl. 3), 3-7 (2004).
13. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr. Clin. North Am. 27(2), 187-201 (2004). (Pubitemid 38452762)
14. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 72. Attention deficit hyperacitivity disorder. Diagnosis and management of ADHD in children, young people and adults (2008). Essential guidelines for clinical practice.
15. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J. Atten. Disord. 5(4), 189-202 (2002). Comprehensive review of pharmacological treatments for ADHD in adults. (Pubitemid 44844205)
16. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J. Clin. Psychopharmacol. 24(1), 24-29 (2004). Meta-analysis of studies demonstrating the efficacy of methylphenidate (MPH) for the treatment of ADHD in adults.
17. Stein MA, Blondis TA, Schnitzler ER et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics 98(4 Pt 1), 748-756 (1996).
18. Pelham WE Jr, McBurnett K, Harper GW et al. Methylphenidate and baseball playing in ADHD children: who's on first? J. Consult. Clin. Psychol. 58(1), 130-133 (1990).
19. Darredeau C, Barrett SP, Jardin B, Pihl RO. Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum. Psychopharmacol. 22(8), 529-536 (2007).
20. Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. NICE guidance on ADHD. Diversion and abuse of methylphenidate in light of new guidance. BMJ 337, A2287 (2008). An important reference for MPH prescribers.
21. Wilens TE, Adler LA, Adams J et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J. Am. Acad. Child Adolesc. Psychiatry 47(1), 21-31 (2008).
22. Kaiser NM, Hoza B, Hurt EA. Multimodal treatment for childhood attention-deficit/hyperactivity disorder. Expert Rev. Neurother. 8(10), 1573-1583 (2008).
23. Rollini M, Baud P. Pharmacological treatment of attention-deficit/ hyperactivity disorder in adults. Rev. Med. Suisse 4(165), 1638-1643 (2008).
24. Benner-Davis S, Heaton PC. Attention deficit and hyperactivity disorder: controversies of diagnosis and safety of pharmacological and nonpharmacological treatment. Curr. Drug Saf. 2(1), 33-42 (2007). (Pubitemid 46723168)
25. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 8(4), 4 (2006). Comphrehensive overview comparing different pharmacological treatments for ADHD in adults. (Pubitemid 44541837)
26. Zabik JE, Levine RM, Maickel RP. Drug interactions with brain biogenic amines and the effects of amphetamine isomers on locomotor activity. Pharmacol. Biochem. Behav. 8(4), 429-435 (1978).
27. Swanson J, Gupta S, Lam A et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-ofproduct studies. Arch. Gen. Psychiatry 60(2), 204-211 (2003). (Pubitemid 36173129)
28. Patrick KS, González MA, Straughn AB, Markowitz JS. New methylphenidate formulations for the treatment of attention-deficit/ hyperactivity disorder. Expert Opin. Drug Deliv. 2(1), 121-143 (2005).
29. 14C: studies in man and animals. J. Pharmacol. Exp. Ther. 191(3), 535-547 (1974).
30. Chan YM, Soldin SJ, Swanson JM, Deber CM, Thiessen JJ, Macleod S. Gas chromatographic/mass spectrometric analysis of methylphenidate (ritalin) in serum. Clin. Biochem. 13(6), 266-272 (1980).
31. Patrick KS, Ellington KR, Breese GR. Distribution of methylphenidate and p-hydroxymethylphenidate in rats. J. Pharmacol. Exp. Ther. 231(1), 61-65 (1984).
32. Modi NB, Wang B, Hu WT, Gupta SK. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm. Drug Dispos. 21(1), 23-31 (2000). (Pubitemid 30808659)
33. Rochdi M, González MA, Dirksen SJ. Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule. Int. J. Clin. Pharmacol. Ther. 42(5), 285-292 (2004). (Pubitemid 38679018)
34. Modi NB, Wang B, Noveck RJ, Gupta SK. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J. Clin. Pharmacol. 40(10), 1141-1149 (2000).
35. Pelham WE, Gnagy EM, Burrows-Maclean L et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107(6), E105 (2001). Examines the characteristics of osmotic-release oral system (OROS)-MPH compared with immediate-release methylphenidate.
36. Swanson JM, Volkow ND. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci. Biobehav. Rev. 27(7), 615-621 (2003).
37. Auiler JF, Liu K, Lynch JM, Gelotte CK. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall Food Evaluation (CAFE) study. Curr. Med. Res. Opin. 18(5), 311-316 (2002). (Pubitemid 35014548)
38. Markowitz JS, Straughn AB, Patrick KS et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin. Pharmacokinet. 42(4), 393-401 (2003).
39. González MA, Pentikis HS, Anderl N et al. Methylphenidate bioavailability from two extended-release formulations. Int. J. Clin. Pharmacol. Ther. 40(4), 175-184 (2002). (Pubitemid 34296385)
40. Greenhill LL. Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr. Clin. North Am. (1), 1-27 (1992).
41. Gatley SJ, Volkow ND, Gifford AN et al. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology (Berl.) 146(1), 93-100 (1999).
42. Volkow ND, Wang GJ, Fowler JS et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 155(10), 1325-1331 (1998).
43. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J. Atten. Disord. 6(Suppl. 1), S31-S43 (2002). A study into the neurochemistry of MPH in the treatment of ADHD. (Pubitemid 44850815)
44. Patrick KS, Caldwell RW, Ferris RM, Breese GR. Pharmacology of the enantiomers of threo-methylphenidate. J. Pharmacol. Exp. Ther. 241(1), 152-158 (1987).
45. Volkow ND, Wang GJ, Fowler JS et al. "Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse 44(3), 175-180 (2002).
46. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav. Brain Res. 94(1), 127-152 (1998).
47. Seeman P, Madras B. Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. Behav. Brain Res. 130(1-2), 79-83 (2002). (Pubitemid 34195323)
48. Wachtel H, Kandel ER. A direct synaptic connection mediating both excitation and inhibition. Science 158(805), 1206-1208 (1967).
49. Chuang TT, Iacovelli L, Sallese M, De Blasi A. G protein-coupled receptors: heterologous regulation of homologous desensitization and its implications. Trends Pharmacol. Sci. 17(11), 416-421 (1996). (Pubitemid 26401700)
50. Biederman J, Mick E, Surman C et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry. 59(9), 829-835 (2006). Placebo-controlled trial on the use of OROS-MPH for the treatment of ADHD in adults.
51. Biederman J, Mick EO, Surman C et al. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 7, 49 (2007). (Pubitemid 350111687)
52. Medori R, Ramos-Quiroga JA, Casas M et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 63(10), 981-989 (2008). Placebo-controlled trial studying the use of OROS-MPH for the treatment of ADHD in adults, including data from different clinical settings.
53. Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J. Clin. Psychiatry 68(1), 93-101 (2007). (Pubitemid 46220130)
54. Biederman J, Mick E, Spencer T et al. An open-label trial of OROS methylphenidate in adults with late-onset ADHD. CNS Spectr. 11(5), 390-396 (2006). (Pubitemid 43727139)
55. Fallu A, Richard C, Prinzo R, Binder C. Does OROS-methylphenidate improve core symptoms and deficits in executive function? results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr. Med. Res. Opin. 22(12), 2557-2566 (2006). Open-label study into the effects of OROS-MPH on executive function in adults with ADHD. (Pubitemid 46048371)
56. Ramos-Quiroga JA, Bosch R, Castells X et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 22(7), 603-611 (2008). Naturalistic study assessing treatment adherence in adults with ADHD receiving OROS-MPH. (Pubitemid 351836038)
57. Spencer T, Biederman J, Wilens T et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 57(5), 456-463 (2005). (Pubitemid 40311979)
58. Sobanski E. Psychiatric comorbidity in adults with attention-deficit/ hyperactivity disorder (ADHD). Eur. Arch. Psychiatry Clin. Neurosci. 256(Suppl. 1), I26-I31 (2006). (Pubitemid 44411277)
59. Ramos-Quiroga JA, Bosch R, Casas M. El TDAH en la edad adulta. In: El Alumno con TDAH. Guía Pràctica Para Educadores. Mena B, Nicolau R, Salat L, Tort P, Romero B (Eds). Ediciones Mayo, Barcelona, Spain 43-46 (2006). Interesting chapter on the management of ADHD at school.
60. Ramos-Quiroga JA, Bosch-Munso R, Castells-Cervello X, Nogueira-Morais M, Garci a-Gimenez E, Casas-Brugue M. Attention deficit hyperactivity disorder in adults: a clinical and therapeutic characterization. Rev. Neurol. 42, 600-606 (2006). (Pubitemid 47378348)
61. Bekker EM, Overtoom CC, Kooij JJ, Buitelaar JK, Verbaten MN, Kenemans JL. Disentangling deficits in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 62(10), 1129-1136 (2005). Evaluates primary deficits and executive function in adults with ADHD.
62. Aron AR, Dowson JH, Sahakian BJ, Robbins TW. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 54(12), 1465-1468 (2003).
63. Parasrampuria DA, Schoedel KA, Schuller R et al. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J. Clin. Pharmacol. 47(12), 1476-1488 (2007). (Pubitemid 350115303)
64. Bayes M, Ramos JA, Cormand B et al. Large-scale genotyping in research into autism spectrum disorders and attention deficit hyperactivity disorder. Rev. Neurol. 40(Suppl. 1), S187-S190 (2005).
65. Ribases M, Hervas A, Ramos-Quiroga JA et al. Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/hyperactivity disorder: contribution of ciliary neurotrophic factor receptors, neurotrophic factor receptor 3, and neurotrophic tyrosine kinase receptor 2. Biol. Psychiatry 63(10), 935-945 (2008).
66. Ramos-Quiroga JA, Ribases-Haro M, Bosch-Munso R, Cormand-Rifa B, Casas M. Genetic advances in attention deficit hyperactivity disorder. Rev. Neurol. 44(Suppl. 3), S51-S52 (2007).
67. Castellanos FX, Lee PP, Sharp W et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/ hyperactivity disorder. JAMA 288, 1740-1748 (2002). Reference study on structural and developmental deficits in children with ADHD.
68. Seidman LJ, Valera EM, Makris N. Structural brain imaging of attention-deficit/hyperactivity disorder. Biol. Psychiatry 57(11), 1263-1272 (2005). An overview of the structural deficits in adults with ADHD. (Pubitemid 40798545)
69. Bush G, Frazier JA, Rauch SL et al. Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop. Biol. Psychiatry. 45, 1542-1552 (1999). (Pubitemid 29292830)
70. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol. Psychiatry. 57(11), 1273-1284 (2005). (Pubitemid 40798546)
71. Valera EM, Faraone SV, Biederman J, Poldrack RA, Seidman LJ. Functional neuroanatomy of working memory in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 57(5), 439-447 (2005). An experimental study of neurofunctional deficits in adults with ADHD. (Pubitemid 40311977)
72. Rommelse NN, Altink ME, Martin NC et al. Neuropsychological measures probably facilitate heritability research of ADHD. Arch. Clin. Neuropsychol. 23(5), 579-591 (2008).
73. Wodka EL, Mostofsky SH, Prahme C et al. Process examination of executive function in ADHD: sex and subtype effects. Clin. Neuropsychol. 22(5), 826-841 (2008).
74. Dresel S, Krause J, Krause KH et al. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur. J. Nucl. Med. 27, 1518-1524 (2000). (Pubitemid 30780247)
75. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci. Lett. 285, 107-110 (2000). (Pubitemid 30227631)
76. Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol. Psychiatry 57, 1410-1415 (2005). Interesting study on the biological effects of MPH in the human brain.
77. Ribases M, Ramos-Quiroga JA, Hervas A et al. Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/ hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol. Psychiatry. 14(1), 71-85 (2009). Genetic study of the common chilhood and adulthood ADHD susceptibility factors regarding the serotoninergic system.